FlandersBio on Twitter

Follow us on Twitter

Archive for February 2014 - News

Archive for February 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis clinical studies

28.02.2014

Galapagos NV (Euronext: GLPG) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis. read more

MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results

27.02.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros. read more

ABLYNX ANNOUNCES 2013 FULL YEAR RESULTS

27.02.2014

Ablynx [Euronext Brussels: ABLX] today announced its consolidated results for 2013, which have been prepared in accordance with IFRS as adopted by the European Union. read more

Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

25.02.2014

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that it has strengthened its IP portfolio following the United States Patent and Trademark Office (“USPTO”) issuing of a Notice of Allowance for patent application number US 12/994,626. read more

Thrombogenics’ Board Announces Decision to Explore Strategic Options for the Company

24.02.2014

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announced that the Board has decided to explore strategic options for the Company. This decision is intended to increase the Company’s ability to realize the significant commercial potential of JETREA® in the US, and to fully capitalize on the Company’s proven product development capabilities. read more

ConfirmMDx for Prostate Cancer Test Featured in ONCOLOGY

24.02.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the ConfirmMDx® for Prostate Cancer test was highlighted as one of several key advances in biomarker technology that aims to transform detection of prostate cancer and its subsequent management. In a review published in the February 2014 issue of ONCOLOGY, leading urologists, E. David Crawford, MD, Neal D. Shore, MD and co-author Karen Ventii, PhD, explain how an explosion in genomic analysis and interpretation of prostate cancer tissue has enabled discovery of new biomarkers, their integration into clinical practice, and clinical management of the disease. read more

Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD

21.02.2014

Galapagos NV (Euronext: GLPG) announced today that the Company will present posters on GLPG0634 and GLPG0974 at the European Crohn's and Colitis Organisation annual meeting, taking place from 20 to 22 February 2014 in Copenhagen, Denmark. The full abstracts can be accessed through the ECCO website. read more

MDxHealth Secures Agreement with Prime Health Services PPO Network Providing Increased Access to ConfirmMDx for Prostate Cancer

20.02.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an agreement with Prime Health Services, Inc. ("Prime Health") a Preferred Provider Organization (PPO) network. This agreement covers all 50 states, offering patients greater access to MDxHealth's ConfirmMDx® for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 144 million covered lives throughout the U.S. read more

ABLYNX WILL ANNOUNCE FULL YEAR RESULTS 2013 WITH WEBCAST

20.02.2014

Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2013 on Thursday 27 February 2014 at 7.00 am CET. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print